Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Patent
• Report
• Software

Filter by year:

Filter from 2024202320222021202020192018201720162015201420132012201120102009200820072006 to Filter to 2024202320222021202020192018201720162015201420132012201120102009200820072006

---

Search results

• Conference paper
  Radhakrishnan ST, Alexander JL, Mullish BH, Danckert N, Garcia MV, Serrano Contreras JI, Balarajah S, Perry R, Gallagher KI, Hicks LC, Powell N, Orchard TR, Li J, Marchesi J, Timothy Williams HRet al., 2024,

  P126 Gut microbiota composition and functionality in a thiopurine-naïve cohort of inflammatory bowel disease (IBD) can differentiate between clinical outcomes

  , BSG LIVE’24, 17-20 June 2024, ICC Birmingham, Publisher: BMJ Publishing Group Ltd and British Society of Gastroenterology, Pages: A126-A127
  • Publisher Web Link
  • Cite
• Journal article
  Mullish BH, Michael DR, Dabcheva M, Webberley TS, Coates N, John DA, Wang D, Luo Y, Plummer SF, Marchesi JRet al., 2024,

  Authors' reply to letter: He who controls Clostridia and Bacteroidia controls the gut microbiome: The concept of targeted probiotics to restore the balance of keystone taxa in irritable bowel syndrome

  , Neurogastroenterology & Motility, Vol: n/a, ISSN: 1350-1925
  • Author Web Link
  • Cite
• Journal article
  Perry RW, Mullish BH, Alexander JL, Shah R, Danckert NP, Blanco JM, Roberts L, Liu Z, Chrysostomou D, Radhakrishnan ST, Balarajah S, Barry R, Hicks LC, Williams HR, Marchesi Jet al., 2024,

  Sa1889 3D Printed rectal swabs for assessing the gut microbiome, metabolome, and inflammation

  , Gastroenterology, Vol: 166, Pages: S566-S567, ISSN: 0016-5085
  • Publisher Web Link
  • Open Access Link
  • Cite
• Conference paper
  King OG, Yip AY, Horrocks V, Blanco JM, Marchesi J, Mullish BH, Clarke TB, McDonald JAet al., 2024,

  Sa1927 ANTIBIOTIC TREATMENT PROMOTES THE INTESTINAL COLONISATION OF VANCOMYCIN-RESISTANT ENTEROCOCCUS BY KILLING MEMBERS OF THE GUT MICROBIOTA AND DECREASING NUTRIENT COMPETITION

  , Publisher: Elsevier BV, Pages: S-584, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Conference paper
  Radhakrishnan ST, Alexander JL, Mullish BH, Valdivia-Garcia M, Danckert NP, Serrano-Contreras JI, Balarajah S, Perry RW, Gallagher KI, Hicks LC, Powell N, Li JV, Marchesi J, Williams HRet al., 2024,

  Sa1871 THE COMPOSITION AND FUNCTION OF THE GUT MICROBIOTA IN A TREATMENT NAIVE INCEPTION COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) CAN ACCURATELY DIFFERENTIATE IBD PHENOTYPE.

  , Publisher: Elsevier BV, Pages: S-559, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Journal article
  Pitashny M, Kao D, Ianiro G, Mullish B, Nagy G, Urbonas T, Kesten I, Stabholz Y, Kupcinskas J, Franz R, Rondinella D, Tamburini S, Tudlik Z, Masucci L, Quaranta G, Fusco W, Cammarota G, Skieceviciene J, Wong K, Segata N, Paul M, Bar-Yoseph Het al., 2024,

  Lyophilized fecal microbiome transfer for primary Clostridioides difficile infection: a multicenter randomized controlled trial (DONATE Study)

  , Open Research Europe, Vol: 4, Pages: 61-61

  <ns3:p>Background Primary Clostridioides difficile infection (pCDI) carries high recurrence and mortality rates and is globally spread. pCDI is often a consequence of exposure to antibiotics, disrupting the healthy intestinal microbiota composition. Not surprisingly, in this antibiotic-associated infection, failure of the standard antibiotic treatment is high. Frozen fecal microbiota transplantation (FMT), the introduction of the microbial community from a healthy donor, has been shown to be safe and highly effective in cases of recurrent CDI, reaching &gt;90% cumulative success rate. Importantly, FMT has shown potential for intestinal decolonization of multidrug-resistant organisms (MDRO), and/or mitigation of their ability to cause invasive infection. The use of FMT for pCDI, has been tested in small studies, showing promising results. The use of frozen FMT graft is often administered via colonoscopy or enteral (naso-jejunal) tubes, which are invasive procedures, placing significant burden on these often frail patients and the institutions providing the services. Moreover, frozen FMT is hampered by storage needs which limit accessibility and spread. Methods We have developed a lyophilized FMT product (Lyo-FMT - a dry compound that does not need freezing) that retains viability, prolongs the shelf time of the product and improves patient acceptance. In a randomized controlled multicenter trial, we aim to assess the efficacy of Lyo-FMT for pCDI in comparison to standard antibiotic therapy. Expected results This easy-to-administer product will restore the microbial community, fight the infective agent and reduce the overall antibiotic-resistant gene burden. This, in turn, will lower the recurrence rate and decrease carriage of other MDRO, coupled with a reduction in antibiotic use. Data on microbial shifts during treatment will shed light on our understanding of the pathophysiology of the disease. Clinicaltrials.gov registration <ns3:bold>NCT05709184

  • Abstract
  • Publisher Web Link
  • Cite
• Conference paper
  Ghani R, Mullish B, Ghazy A, Corbett R, Duncan N, Satta G, Gilchrist M, Williams H, Pavlu J, Innes A, MacDonald J, Miguens Blanco J, Danckert N, Davies F, Marchesi Jet al., 2024,

  P3438 – Intestinal microbiota transplantation for patients colonised with multidrug-resistant organisms have an improvement in clinical outcomes associated with a significant increase in alpha-diversity metrics of the gastrointestinal microbiota

  , ESCMID Global, Publisher: Elsevier
  • Author Web Link
  • Cite
• Journal article
  Mullish BH, Bak A, Merrick B, Quraishi MN, Goldenberg SD, Williams HRTet al., 2024,

  Overview of the second edition of the joint British Society of Gastroenterology and Healthcare Infection Society faecal microbiota transplant guidelines, 2024

  , Journal of Hospital Infection, ISSN: 0195-6701
  • Cite
• Journal article
  Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Punčochář M, Ernst S, Logan D, Belanger K, Esfahani K, Richard C, Ninkov M, Piccinno G, Armanini F, Pinto F, Krishnamoorthy M, Figueredo R, Thebault P, Takis P, Magrill J, Ramsay L, Derosa L, Marchesi JR, Parvathy SN, Elkrief A, Watson IR, Lapointe R, Segata N, Haeryfar SMM, Mullish BH, Silverman MS, Burton JP, Maleki Vareki Set al., 2024,

  Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

  , Nature Medicine, Vol: 30, Pages: 604-604, ISSN: 1078-8956
  • Publisher Web Link
  • Cite
• Journal article
  Kragsnaes MS, Jensen JRB, Nilsson AC, Malik MI, Munk HL, Pedersen JK, Horn HC, Kruhoffer M, Kristiansen K, Mullish BH, Marchesi JR, Kjeldsen J, Roettger R, Ellingsen Tet al., 2024,

  Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial

  , RMD OPEN, Vol: 10, ISSN: 2056-5933
  • Open Access Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.